Company News
J&J announces the approval of TECNIS Synergy and TECNIS Synergy Toric II IOLs
Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announced the U.S. Food and Drug Administration (FDA) approval of TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs, and the Health Canada approval of TECNIS Synergy™ Toric II IOLs. This next-generation PCIOL is built on the legacy TECNIS® platform and delivers the widest range of continuous vision with the best near vision among leading PCIOLs, 3,4,6,7,8 † superior contrast even in low-light conditions, and reduced spectacle wear.1,2,3,4,8 In a company sponsored study, 9 out of 10 patients who received TECNIS Synergy™ IOL lenses did not need glasses after surgery.9 ††
Cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes,10 with more than 90% of people developing cataracts by the age of 65.11 Over the last two decades, cataract patients’ visual needs have dramatically changed as digital devices have become an integral part of their daily lives.12 The rapid shift to digital platforms has increased demand from cataract patients for high-quality vision, from distance-to-intermediate-to-near, in all lighting conditions.
“In the past 10 months of implanting the TECNIS Synergy™ IOL lens, I have seen excellent visual performance at all distances, and in a wide variety of lighting conditions, with most patients achieving freedom from glasses,” said Dr. Ike Ahmed,*** Assistant Professor and Director of the Glaucoma and Advanced Anterior Surgical Fellowship, University of Toronto in Canada. “Having used the TECNIS® Toric II platform in other TECNIS® lenses, I’m eager to use the TECNIS Synergy™ Toric II IOL in patients that require astigmatism correction.”
The TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs are among the latest surgical vision innovations from Johnson & Johnson Vision to receive FDA and Health Canada approval. Over the past year, the company has received clearance or approval across North America for seven innovations designed to be used in the treatment of cataract patients, including the TECNIS Eyhance™ IOLs.
“The TECNIS Synergy™ IOL combines the best of extended depth of focus and multifocal technologies – to deliver the widest range of continuous vision with the best near vision among leading PCIOLs, 3,4,6, 7† without the visual gaps caused by existing trifocal technology,” ††† said Rajesh Rajpal, Chief Medical Officer and Global Head of Clinical and Medical Affairs at Johnson & Johnson Vision. “Additionally, we’ll offer TECNIS Synergy™ IOL on our new Toric II platform, when it launches later this year, to give surgeons the ability to address astigmatism at the time of surgery.”
The TECNIS Synergy™ IOL was first launched in Europe and Asia Pacific in 2019 and is currently available in Latin America and Canada. The full TECNIS Synergy™ IOL family will be available across North America this summer. PR Newswire
